Rapid N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Kit As a Differentiating Tool for Acute Dyspnea in a Resource-Limited Setting

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2023 Dec 7

PMID 38058332

Authors

Sweta Sahu

Devarsh N Shah

Roopeessh Vempati

Pallavi Roy Kandhi

Mihirkumar P Parmar

Sanjay Bethanabotla

Shardool Gadgil

Prerna Chandra

Sangamesh N Malipatil

Yash Patel

Balaganesh Natarajan

Thrilok Chander Bingi

Affiliations

Soon will be listed here.

Abstract

Introduction Dyspnea is among the most prevalent symptoms experienced by patients presenting as an emergency. The underlying etiology is often a cardiovascular or pulmonary condition, of which heart failure is recognized as a major contributor. The differentials are primarily established based on the patient's clinical presentation and physical examinations but are not conclusive. Of the various investigations undertaken to determine the cause of dyspnea, the biomarker N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) was found to be significantly associated with heart failure. Its level has been proven to be in direct correlation with the severity of the disease. This study demonstrates the usability of an economical rapid test kit in measuring NT-ProBNP levels to help differentiate the cause of dyspnea in the presenting patient in a resource-limited setting. Methodology We studied 115 participants from a tertiary care center in India, which included 70 males and 45 females aged ≤30 to ≥75 years, presenting with shortness of breath. Rapid NT-ProBNP tests were conducted alongside recording their symptoms, vitals, examination findings, and other parameters. They were also classified according to New York Heart Association (NYHA) Classification, and further investigated. Results The study elucidated the efficacy and accuracy of the rapid kits in determining NT-ProBNP levels, and its relation with the severity and prognosis of heart failure. The kits utilized had a sensitivity of greater than 93% for ruling out heart failure as a cause of dyspnea, and a sensitivity of greater than 96% for ruling out elevated NT-ProBNP levels in general. Other parameters such as presenting symptoms and vitals were also analyzed, establishing a correlation with NT-ProBNP levels. Conclusion This study guided us in understanding the effective utilization of the rapid testing kits for emergency care, minimizing the burden on other limited resources. The lower cost and ease of use would serve as a quick means of reaching a conclusive diagnosis, especially in an emergency, which in turn would aid in receiving timely and specific treatment. These kits could act as a stepping stone in creating a sustainable and efficient healthcare system for patients as well as healthcare workers.

References

ODonoghue M, Chen A, Baggish A, Anwaruddin S, Krauser D, Tung R . The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J Card Fail. 2005; 11(5 Suppl):S9-14. DOI: 10.1016/j.cardfail.2005.04.011. View

Morrison L, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A . Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002; 39(2):202-9. DOI: 10.1016/s0735-1097(01)01744-2. View

Maisel A, Hollander J, Guss D, McCullough P, Nowak R, Green G . Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004; 44(6):1328-33. DOI: 10.1016/j.jacc.2004.06.015. View

Lee-Lewandrowski E, Januzzi J, Green S, Tannous B, Wu A, Smith A . Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics GmbH Elecsys proBNP assay. Clin Chim Acta. 2007; 386(1-2):20-4. DOI: 10.1016/j.cca.2007.07.015. View

Lee Y, Choi D, Kim G . Development of a Rapid Diagnostic Kit for Congestive Heart Failure Using Recombinant NT-proBNP Antigen. Medicina (Kaunas). 2021; 57(8). PMC: 8398600. DOI: 10.3390/medicina57080751. View

Maisel A . B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Rev Cardiovasc Med. 2002; 3 Suppl 4:S10-7. View

Mentz R, Felker G . Noncardiac comorbidities and acute heart failure patients. Heart Fail Clin. 2013; 9(3):359-67, vii. PMC: 3906631. DOI: 10.1016/j.hfc.2013.04.003. View

Berliner D, Schneider N, Welte T, Bauersachs J . The Differential Diagnosis of Dyspnea. Dtsch Arztebl Int. 2017; 113(49):834-845. PMC: 5247680. DOI: 10.3238/arztebl.2016.0834. View

Wong J, Lu W, Wu K, Liu M, Chen G, Kuo C . A comparative study of pulse rate variability and heart rate variability in healthy subjects. J Clin Monit Comput. 2012; 26(2):107-14. DOI: 10.1007/s10877-012-9340-6. View

10.

Purna Shrestha A, Shrestha R, Shrestha S, Pradhan A . Prevalence of Dyspnea among Patients Attending the Emergency Department of a Tertiary Care Hospital: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc. 2020; 57(219):302-306. PMC: 7580447. View

11.

Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T . The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail. 2005; 7(4):537-41. DOI: 10.1016/j.ejheart.2005.01.022. View

12.

Smith G, Prytherch D, Watson D, Forde V, Windsor A, Schmidt P . S(p)O(2) values in acute medical admissions breathing air--implications for the British Thoracic Society guideline for emergency oxygen use in adult patients?. Resuscitation. 2012; 83(10):1201-5. DOI: 10.1016/j.resuscitation.2012.06.002. View

13.

Wahls S . Causes and evaluation of chronic dyspnea. Am Fam Physician. 2012; 86(2):173-82. View

14.

Inoue Y, Kawayama T, Iwanaga T, Aizawa H . High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med. 2009; 48(7):503-12. DOI: 10.2169/internalmedicine.48.1701. View

15.

Doust J, Lehman R, Glasziou P . The role of BNP testing in heart failure. Am Fam Physician. 2006; 74(11):1893-8. View

16.

Omland T . Heart failure in the emergency department: is B-type natriuretic peptide a better prognostic indicator than clinical assessment?. J Am Coll Cardiol. 2004; 44(6):1334-6. DOI: 10.1016/j.jacc.2004.07.016. View

17.

MORGAN W, Hodge H . Diagnostic evaluation of dyspnea. Am Fam Physician. 1998; 57(4):711-6. View

18.

van Riet E, Hoes A, Limburg A, Landman M, Van der Hoeven H, Rutten F . Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail. 2014; 16(7):772-7. DOI: 10.1002/ejhf.110. View

19.

Zhang C, Huang D, Shen D, Zhang L, Wang Y, Sun H . Brain Natriuretic Peptide as the long-term cause of mortality in patients with cardiovascular disease: a retrospective cohort study. Int J Clin Exp Med. 2015; 8(9):16364-8. PMC: 4659046. View

20.

Chandy G, Sathyendra S, Pichamuthu K, Hazra D, Abhilash K . Differentiating Cardiac and Pulmonary Causes of Dyspnea Using Ultrasonography and Dyspnea Discrimination Index. Indian J Crit Care Med. 2022; 26(1):33-38. PMC: 8783246. DOI: 10.5005/jp-journals-10071-24089. View